Glaukos Corporation (GKOS) is a Medical - Devices company in the Healthcare sector, currently trading at $120.52. It has a SharesGrow Score of 52/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is GKOS = $143 (+19% upside).
Valuation: GKOS trades at a trailing Price-to-Earnings (P/E) of -35.6 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.2.
Financials: revenue is $507M, +21.8%/yr average growth. Net income is $188M (loss), growing at -24.2%/yr. Net profit margin is -37% (negative). Gross margin is 55.7% (-19.9 pp trend).
Balance sheet: total debt is $140M against $656M equity (Debt-to-Equity (D/E) ratio 0.21, conservative). Current ratio is 4.69 (strong liquidity). Debt-to-assets is 15.6%. Total assets: $893M.
Analyst outlook: 18 / 24 analysts rate GKOS as buy (75%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 92/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 55/100 (Partial), Future 79/100 (Pass), Income 10/100 (Fail).
